Can HIV-1 viral interference be used therapeutically?

The Lancet Infectious Diseases

Volumn 13, Issue 1, 2013, Pages 9-10

  Vento, Sandro ^a   Cainelli, Francesca ^a  

^a UNIVERSITY OF BOTSWANA   (Botswana)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS ANTIBODY; HEPATITIS VACCINE; NONSTRUCTURAL PROTEIN 5A; TAX PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN T CELL LEUKEMIA VIRUS 2; LETTER; MIXED INFECTION; PRIORITY JOURNAL; VIRUS INTERFERENCE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

COINFECTION; HIV INFECTIONS; HIV-1; HUMANS; VIRAL INTERFERENCE; VIRAL VACCINES;

EID: 84871043457     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70312-2     Document Type: Letter

References (15)

1. Vahidnia F, Petersen M, Stapleton JT, Rutherford GW, Busch M, Custer B Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis 2012, 55:1012-1019.
2. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001, 285:1592-1601.
3. Esbjörnsson J, Månsson F, Kvist A, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012, 367:224-232.
4. Casoli C, Pilotti E, Bertazzoni U Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev 2007, 9:140-149.
5. Brites C, Sampaio J, Oliveira A HIV/human T-cell lymphotropic virus coinfection revisited: Impact on AIDS progression. AIDS Rev 2009, 11:8-16.
6. Van Asten L, Prins M Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 2004, 18:2319-2324.
7. Corey L Synergistic copathogens: HIV-1 and HSV-2. N Engl J Med 2007, 356:854-856.
8. Bhattarai N, Stapleton JT GB virus C: the good boy virus?. Trends Microbiol 2012, 20:124-130.
9. Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis 1999, 179:783-789.
10. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001, 345:715-724.
11. Al-Harthi L, Owais M, Arya SK Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1998, 14:59-64.
12. Schindler M, Münch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067.
13. Pilotti E, Elviri L, Vicenzi E, et al. Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood 2007, 109:1850-1856.
14. Gretch D Advocating the concept of GB virus C biotherapy against AIDS. Clin Infect Dis 2012, 55:1020-1021.
15. Sanchez-Martin MJ, Busquets MA, Girona V, Haro I, Alsina MA, Pujol M Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models. Biochim Biophys Acta 2011, 1808:2178-2188.